Shah Smital has filed 3 insider transactions across 3 companies since July 2023.
Most recent transaction: a grant/award of 140000 shares of Lyell Immunopharma, Inc. ($LYEL) on March 09, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 9, 2026 | Lyell Immunopharma, Inc. | $LYEL | Shah Smital | Chief Fin. and Bus. Officer | A | Option (right to buy) | 140000 | $0.00 | 140,000.0000 | 21,218,217 | 9999.99% | 0.66% |
| June 13, 2024 | PLIANT THERAPEUTICS, INC. | $PLRX | Shah Smital | Director | A | Common Stock (Right to Buy) | 26764 | $0.00 | 26,764.0000 | 0 | 9999.99% | 0.00% |
| July 19, 2023 | LENZ Therapeutics, Inc. | $LENZ | Shah Smital | Director | A | Stock Option (right to buy) | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |